financetom
Business
financetom
/
Business
/
U.S. pizza chain Papa John's targets 2025 India re-entry after delay
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
U.S. pizza chain Papa John's targets 2025 India re-entry after delay
Jan 3, 2025 3:51 AM

(Reuters) - U.S. pizza chain Papa John's International plans to make its return to the Indian market in 2025, a year later than planned, while many Western brands rethink their plans as inflation hits consumer spending.

Papa John's exited India in 2017 saying its restaurants were not able to meet the expectations of the brand and the franchisee.

In the meantime rivals Domino's Pizza and Pizza Hut have become popular as Indians increasingly opt for international cuisine.

India "remains a priority" and the company will open its first restaurants this year, a spokesperson for Papa John's said by email.

Under plans outlined in 2023, the company aimed to scale up to 650 outlets over a decade.

"India is a complex market with unique consumer preferences. We are taking the necessary time to ensure our franchise partner opens with the right products and menu, technology, and restaurant footprint to ensure their long-term success," the company said.

Inflation is also squeezing middle class budgets, prompting some players to slow expansion plans.

India's Tata Consumer Products, which operates Starbucks stores under a joint venture, is pushing back plans for some new outlets until later in its schedule.

Consumer analysts in India still believe in the longer-term prospects for Western fast-food brands in the country noting its growing eating-out culture and urbanisation of smaller towns.

Papa John's has more than 5,900 locations in about 50 countries and territories, according to its website.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
Apr 3, 2025
(Reuters) -The U.S. Food and Drug Administration has approved expanded use of Amgen's ( AMGN ) drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition, the regulator said on Thursday. The drug, also known as inebilizumab, has now become the first FDA-approved treatment for Immunoglobulin G4-related disease (IgG4-RD), a rare condition in...
Merck Investors Have 'Limited Appetite' Returning to the Stock Ahead of Gardasil Reassessment, UBS Says
Merck Investors Have 'Limited Appetite' Returning to the Stock Ahead of Gardasil Reassessment, UBS Says
Apr 3, 2025
03:22 PM EDT, 04/03/2025 (MT Newswires) -- Merck ( MRK ) investors have limited near-term appetite to return to the stock as Gardasil inventory remains elevated in China, with a key reassessment of demand not expected until mid-2025, UBS Securities said in a note emailed Thursday. The firm estimates Q1 revenue at $15.4 billion, slightly below the $15.6 billion consensus,...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
Apr 3, 2025
April 3 (Reuters) - The U.S. Food and Drug Administration has approved expanded use of Amgen's ( AMGN ) drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition, the regulator said on Thursday. The drug, also known as inebilizumab, has now become the first FDA-approved treatment for Immunoglobulin G4-related disease (IgG4-RD), a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved